Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: Clinical, structural and safety results

Rheumatology (United Kingdom)

Volumn 56, Issue 10, 2017, Pages 1771-1779

  Smolen, Josef S ^a   Choe, Jung Yoon ^b   Prodanovic, Nenad ^c   Niebrzydowski, Jaroslaw ^d   Staykov, Ivan ^e   Dokoupilova, Eva ^f   Baranauskaite, Asta ^g   Yatsyshyn, Roman ^h   Mekic, Mevludin ⁱ   Porawska, Wieskawa ^j   Ciferska, Hana ^k   Jedrychowicz Rosiak, Krystyna ^d   Zielinska, Agnieszka ^l   Choi, Jasmine ^m   Rho, Young Hee ^m  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Catholic University of Daegu   (South Korea)

^c Clinical Center Banja Luka   (Bosnia and Herzegovina)

^d Medica Pro Familia   (Poland)

^e MHAT 'Dr Ivan Seliminski'   (Bulgaria)

^f Divison of Rheumatology   (Czech Republic)

^g LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^h SHEI Ivano Frankivsk NMU   (Ukraine)

ⁱ University Clinical Centre of Sarajevo   (Bosnia and Herzegovina)

^j Poznanski Osrodek Medyczny NOVAMED   (Poland)

^k INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^l Divison of Rheumatology   (Poland)

^m Samsung Bioepis Co Ltd   (South Korea)

more..

Author keywords

Biosimilar; Flixabi; Infliximab; Monoclonal antibody; Radiographic progression; Remicade; Renflexis; Rheumatoid arthritis; Sharp score; Tumour necrosis factor blocker

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOSIMILAR AGENT; DRUG ANTIBODY; FOLIC ACID; INFLIXIMAB; METHOTREXATE; SB 2; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BIOLOGICAL THERAPY; BREAST CANCER; BRONCHITIS; CLINICAL DISEASE ACTIVITY INDEX; CONGESTIVE HEART FAILURE; COUGHING; DAS28; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPEPSIA; FEVER; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGENICITY; INCIDENCE; INFUSION RELATED REACTION; JOINT RADIOGRAPHY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; PARALLEL DESIGN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RASH; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SHARP SCORE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VISUAL ANALOG SCALE; ADULT; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; MALE; MIDDLE AGED; PROCEDURES; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85029779740     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex254     Document Type: Article

References (35)

1. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
2. Braun J, van den Berg R, Baraliakos X et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
3. Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510
4. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9
5. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
6. Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206
7. Dö rner T, Strand V, Cornes P et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;75:974-82
8. Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 2013;12:835-8
9. Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 2011;33:679-707
10. European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04Rev1. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2014/10/WC500176768.pdf (2 October 2016, date last accessed)
11. US Food and Drug Administration. Biologics price competition and innovation. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ ucm216146.pdf. (2 October 2016, date last accessed)
12. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. EMA/CHMP/BMWP/ 403543/2010. 2012. http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2012/06/ WC500128686.pdf. (7 November 2016, date last accessed)
13. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. http://www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM291128.pdf. (2 October 2016, date last accessed)
14. Remicade Prescribing Information. Janssen Biotech, Inc. April 2016. http://www.janssen.com/australia/sites/www_ janssen_com_australia/files/product/pdf/remicade_pi.pdf. (27 February 2017, date last accessed)
15. Shin D, Kim Y, Kim YS, Kö rnicke T, Fuhr R. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade®) in healthy subjects. Biodrugs 2015;29:381-8
16. Choe J-Y, Prodanovic N, Niebrzydowski J et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2015;76:58-64
17. Lipsky PE, van der Heijde D, St. Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602
18. Smolen JS, Han C, van der Heijde DM et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockage. Ann Rheum Dis 2009;68:823-7
19. European Medicines Agency. Remicade: EPAR-product information (SmPC). 2016. http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/ human/000240/WC500050888.pdf (27 February 2017, date last accessed)
20. Fries JF, Spitz P, Kraines RG et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45
21. Anderson J, Caplan L, Yazdany J et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 2012;64:640-7
22. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13
23. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5
24. Shankar G, Arkin S, Cocea L et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014;16:658-73
25. Souto A, Maneiro JR, Gó mez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systemic review and meta-analysis of drug registries and health care databases. Rheumatology 2016;55:523-34
26. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-81
27. Navarro-Compá n V, Gherghe AM, Smolen JS et al. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systemic literature review. Rheumatology 2015;54:994-1007
28. Smolen JS, Han C, Bala M et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30
29. Binder NB, Puchner A, Niederreiter B et al. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum 2013;65:608-17
30. Rahman MU, Strusberg I, Geusens P et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-8
31. Yoo DH, Racewicz A, Brzezicki J et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2016;18:82
32. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013;72:1589-93
33. Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis 2017;76:4-6
34. Obama B. United States Health Care Reform. JAMA 2016;316:525-32
35. Kay J. Editorial: biosimilars: new or dé jàvu? Arthritis Rheum 2016;68:1049-52